Kneat: Streamlining Compliance in Life Sciences
Kneat is redefining how life sciences companies handle regulatory compliance, one digital document at a time.
Digital validation software gains traction across major pharmaceutical giants
In an industry where every step must be documented and regulatory compliance is non-negotiable, Kneat is helping life sciences companies reduce costs and improve accuracy. Their digital validation platform has become the go-to choice for eight of the ten largest pharmaceutical companies worldwide. With customers like Merck rolling out Kneat across 27 global sites and over 12,000 users, the company is scaling rapidly. Offering a significant reduction in cycle time, documentation labor, and compliance errors, Kneat has seen its revenue climb 32% year-over-year in 2025. And with market penetration still low, the $2B total addressable market for digital validation remains largely untapped.
For more information on Kneat.com, Inc. (TSX: KSI, OTC: KSIOF) please click on the request investor info button.
Latest Articles
Hot Companies
You might also like
Picard Medical / SynCardia Tackling One of the Largest Unmet Needs in Cardiovascular Medicine
Advanced heart failure continues to rise globally, while the supply of donor hearts remains limited. This structural imbalance creates a significant and expanding market opportunity, with thousands of patients each year lacking viable treatment options and placing growing economic pressure on healthcare systems.
BTV Visits Atlas Salt, Graphene Manufacturing, Telescope Innovations, Nevada Organic Phosphate, Maple Gold, Intrepid Metals and Nine Mile Metals
As the resource cycle accelerates, BTV – Business Television highlights companies turning exploration, innovation and strategic growth into actionable opportunity.
